The inflection point facing life sciences
In this guest blog, BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, reflects on the evolving investment landscape in life sciences.
The piece explores how a period of tighter capital and greater scrutiny has reshaped expectations around execution, value creation and operational discipline and why renewed confidence is beginning to emerge across the sector as we move into 2026.
Over the last two years, conversations in life sciences have increasingly reflected a noticeable change in sentiment. Capital has persisted, though deployed with far greater discipline. Valuations recalibrated, development timelines were examined more closely, and leadership teams pivoted from growth-at-all-costs to operational discipline. For builders in the sector, this period felt less like a temporary slowdown and more like an extended proving ground: demonstrate the science, demonstrate execution, and demonstrate a credible route to value.
Importantly, 2025 was not a year lost. It was a year defined by selectivity, with capital flowing into a smaller number of high-conviction opportunities, while many others prioritised preservation, focus, and resilience.
As we enter 2026, the narrative is beginning to evolve. Not because the market is reverting to earlier exuberance, but because there is growing clarity around what will be funded, why it will be funded, and how “quality” is now assessed. Innovation never stopped during the reset; what’s returning is visibility, confidence, and the sense that disciplined companies are once again positioned to move forward.
What looked like a pullback was a rebalance
The recent slowdown was not a failure of life sciences; it was a correction. Higher interest rates changed the cost of capital and forced a reassessment of risk. In a sector defined by long development timelines and high capital intensity, that recalibration landed hard. But the underlying science did not weaken.
If anything, the reset rewarded discipline. Companies became more focused on where they can win, more deliberate about how they build evidence, and more realistic about routes to commercialisation. The result has been a stronger culture of prioritisation: fewer distractions, tighter pipelines, and sharper thinking about what value creation actually means.
What this means: the bar is higher, but that is exactly what makes the next phase more investable.
Capital returns with conviction
Over the past year, several funding and investment announcements have signalled renewed confidence. What stands out is not just that money is moving, but that it is moving with a different mindset: fewer speculative bets, more conviction, and greater emphasis on platforms, proof, and delivery.
In the UK, large financings into AI enabled drug discovery have been notable not only for their scale, but for what they represent: investor confidence in approaches that could fundamentally reshape how science is translated into medicine.
Similarly, long-horizon commitments from global biopharma to expand R&D footprints in the UK signal confidence in the country’s research ecosystem, translational capabilities, and long term infrastructure. This is strategic capital. It is not chasing a moment; it is underwriting a direction.
My view is that this is the key shift: we are moving from sentiment driven funding to thesis driven funding. Capital is reengaging selectively, and often with clearer milestones. The bar is higher, but the signal is healthier. When capital returns with intent, it favours companies that can articulate not only what they are building, but why they can build it better than anyone else.
Policy matters more than ever
Another factor shaping this turning point is clearer alignment between policy direction and industry needs. The UK’s renewed life sciences strategy agenda sets out ambitions to improve clinical trial speed, unlock the value of health data responsibly, support advanced manufacturing, and accelerate the adoption of innovation into the health system.
For businesses making long-term decisions, clarity matters. For investors, predictability matters. Policy does not eliminate risk, but it can reduce friction, and friction is one of the most underestimated costs in life sciences. Even incremental improvements to trial setup times, data access, and market pathways compound over years and can meaningfully change the UK’s attractiveness as a place to build and scale.
What this means is that if the UK executes on speed and predictability, it becomes easier to scale here, not simply start here.
Visibility declined, progress did not
One of the biggest misconceptions of the last two years is that innovation slowed, but it did not. Advances in AI enabled drug discovery, precision medicine, cell and gene therapy, and digital health continued throughout the reset. Many companies used the tougher environment to strengthen datasets, refine pipelines, and rethink development plans with greater realism.
As a result, some of the most compelling innovation attracting attention now was built quietly during a more disciplined period. What we are seeing today is not sudden progress, it is delayed visibility.
What this means: the reset didn’t slow innovation; it filtered noise.
Setting the course ahead
Life sciences will always be complex, and it will always carry risk. Not every company will benefit from the next phase, and funding constraints, regulatory demands, and talent competition remain real.
What we see now is a sector moving forward with greater maturity: stronger foundations, sharper focus, and a clearer sense of purpose. That may not generate the same headlines as exuberance once did. Yet it creates something far more valuable durable progress.
As life sciences enters a phase defined less by headlines and more by delivery, informed decisions will matter more than ever. If you are a life sciences company navigating this shift and seeking support, connect with our R&D expert .